Vaccinex shares vroom higher on mystery discovery deals
Feb. 19, 2021
By Michael Fitzhugh
News of Vaccinex Inc. signing two multitarget deals with undisclosed "prominent pharmaceutical companies" sent company shares (NASDAQ:VCNX) up 70% to $4.88 on Feb. 19, even as financial terms of the deal went undisclosed. The collaborations will focus on using the company's ActivMAb antibody discovery and novel viral display platform to develop candidates against complex antigens such as G protein-coupled receptors and ion channels, the company said.
Collaboration Partner: Merck KGaA, Darmstadt, Germany Clinical evaluation of the safety and effectiveness of VX15/2503 in combination with avelumab (anti-PD-L1) in the treatment of advanced non-Small Cell Lung Cancer (NSCLC). ClinicalTrials.gov Identifier: NCT03268057